Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into ...

Zurcher Kantonalbank Zurich Cantonalbank raised its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 3.0% in ...

Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the roles that specific genes play in many diseases. But to date this ...

Gene therapy pioneer Jim Wilson and researcher Kiran Musunuru are using contrasting approaches to overcome “irrational ...

Reuters reported that President Trump’s tariffs have impacted the broader stock markets, weighing on investors’ sentiments, ...

Now, Johns Hopkins Medicine scientists say they have shed new light on how bacteria protect themselves from certain phage ...

Farther Finance Advisors LLC boosted its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 34.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & ...

CRISPR Therapeutics AG (CRSP) closed at $41.17 in the latest trading session, marking a -1.84% move from the prior day.

Bacteria get invaded by viruses called phages.Scientists are studying how bacteria use CRISPR to defend themselves from ...

CRISPR Therapeutics AG (CRSP) closed the latest trading day at $41.22, indicating a +0.12% change from the previous session's end. This change outpaced the S&P 500's 0.08% gain on the day. On the ...

The competition between U.S. and Chinese biotech companies is particularly fierce in one field: CRISPR gene editing. Here are ...

Using CRISPR-based engineering methods to prompt stem cells to organize into embryo-like structures, scientists were able to create 'programmable' cellular models of embryos without ever experimenting ...